International Stem Cell Corporation has begun preclinical testing of a stem cell treatment for retinal disease including macular degeneration and retinitis pigmentosa.
International Stem Cell Corporation has begun preclinical testing of a stem cell treatment for retinal disease including macular degeneration and retinitis pigmentosa.
Researchers have developed retinal layers from parthenogenetic human stem cells, which do not involve the destruction of embryos, and believe this may eventually lead to a sustainable FDA-approved source of human tissue to be used as a treatment for degenerative retinal diseases.
The human tissue has now been implanted into animals, providing models for preclinical testing. If successful, the tissue will be manufactured for further testing.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.